Fund a biopsy at progression, every time, as standard care
When a treatment stops working, the tumour is rarely re-sampled, so nobody learns why. Paying for a biopsy at that moment would build the missing map of resistance.
Resistance mechanisms are known for only a minority of progressions because the sample is never taken: reimbursement is unclear, the patient is unwell, and there is no trial slot. A funded pathway would pay for a paired tissue and plasma sample at every progression on a targeted agent, with rapid sequencing, a mechanism-matched treatment recommendation returned to the clinician, and deposition into a shared database.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Data silos · Records, scans, genomes and outcomes sit in separate systems that cannot talk. Every patient's experience is lost to the next.
Pages like this
not linked directly; found by shared links- IdeaTreat resistance like an infectious disease and run national surveillance
Shares Drug resistance (primary and acquired), Data silos, Acquired resistance to every therapy, Comprehensive genomic profiling.
- IdeaSMART designs to test treatment strategies, not just single drugs
Shares Drug resistance (primary and acquired), Circulating tumour DNA (ctDNA), Acquired resistance to every therapy.
- IdeaOne open atlas of how tumours escape every drug
Shares Drug resistance (primary and acquired), Data silos, Acquired resistance to every therapy.
- IdeaAutonomous closed-loop adaptive therapy driven by blood tests and evolutionary models
Shares Drug resistance (primary and acquired), Circulating tumour DNA (ctDNA), Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaA standing platform trial that assigns treatment by how the tumour escaped
Shares Acquired resistance to every therapy, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
- IdeaCut off the emergency programme cancer cells use to survive treatment
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- IdeaDrop mandatory fresh biopsies where blood or archival tissue would do
Shares Circulating tumour DNA (ctDNA), Comprehensive genomic profiling, Liquid biopsy (ctDNA).